67 related articles for article (PubMed ID: 38563818)
1. Uveal melanomas. Conservation treatment.
Munzenrider JE
Hematol Oncol Clin North Am; 2001 Apr; 15(2):389-402. PubMed ID: 11370500
[TBL] [Abstract][Full Text] [Related]
2. Uveal melanoma: A pathologist's perspective and review of translational developments.
Schoenfield L
Adv Anat Pathol; 2014 Mar; 21(2):138-43. PubMed ID: 24508696
[TBL] [Abstract][Full Text] [Related]
3. Divergent local and systemic antitumor response in primary uveal melanomas.
Lucibello F; Lalanne AI; Le Gac AL; Soumare A; Aflaki S; Cyrta J; Dubreuil L; Mestdagh M; Salou M; Houy A; Ekwegbara C; Jamet C; Gardrat S; Le Ven A; Bernardeau K; Cassoux N; Matet A; Malaise D; Pierron G; Piperno-Neumann S; Stern MH; Rodrigues M; Lantz O
J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38563818
[TBL] [Abstract][Full Text] [Related]
4. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
5. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
6. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
7. Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.
Rothermel LD; Sabesan AC; Stephens DJ; Chandran SS; Paria BC; Srivastava AK; Somerville R; Wunderlich JR; Lee CC; Xi L; Pham TH; Raffeld M; Jailwala P; Kasoji M; Kammula US
Clin Cancer Res; 2016 May; 22(9):2237-49. PubMed ID: 26712692
[TBL] [Abstract][Full Text] [Related]
8. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
[TBL] [Abstract][Full Text] [Related]
9. Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8
Naigeon M; Roulleaux Dugage M; Danlos FX; Boselli L; Jouniaux JM; de Oliveira C; Ferrara R; Duchemann B; Berthot C; Girard L; Flippot R; Albiges L; Farhane S; Saulnier P; Lacroix L; Griscelli F; Roman G; Hulett T; Marabelle A; Cassard L; Besse B; Chaput N
Sci Adv; 2023 Nov; 9(45):eadh0708. PubMed ID: 37939189
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.
Mariani P; Torossian N; van Laere S; Vermeulen P; de Koning L; Roman-Roman S; Lantz O; Rodrigues M; Stern MH; Gardrat S; Lesage L; Champenois G; Nicolas A; Matet A; Cassoux N; Servois V; Romano E; Piperno-Neumann S; Lugassy C; Barnhill R
Br J Cancer; 2023 Sep; 129(5):772-781. PubMed ID: 37443346
[TBL] [Abstract][Full Text] [Related]
11. Determinants of overall survival in patients with metastatic uveal melanoma.
Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
[TBL] [Abstract][Full Text] [Related]
12. Multiorgan Involvement of Dormant Uveal Melanoma Micrometastases in Postmortem Tissue From Patients Without Coexisting Macrometastases.
Gill VT; Norrman E; Sabazade S; Karim A; Lardner E; Stålhammar G
Am J Clin Pathol; 2023 Aug; 160(2):164-174. PubMed ID: 37052618
[TBL] [Abstract][Full Text] [Related]
13. Neoantigens: promising targets for cancer therapy.
Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L
Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431
[TBL] [Abstract][Full Text] [Related]
14. Neglected, yet significant role of FOXP1 in T-cell quiescence, differentiation and exhaustion.
Kaminskiy Y; Kuznetsova V; Kudriaeva A; Zmievskaya E; Bulatov E
Front Immunol; 2022; 13():971045. PubMed ID: 36268015
[TBL] [Abstract][Full Text] [Related]
15. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.
Luoma AM; Suo S; Wang Y; Gunasti L; Porter CBM; Nabilsi N; Tadros J; Ferretti AP; Liao S; Gurer C; Chen YH; Criscitiello S; Ricker CA; Dionne D; Rozenblatt-Rosen O; Uppaluri R; Haddad RI; Ashenberg O; Regev A; Van Allen EM; MacBeath G; Schoenfeld JD; Wucherpfennig KW
Cell; 2022 Aug; 185(16):2918-2935.e29. PubMed ID: 35803260
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
